Montreal-based CRO Innovaderm Research has rebranded immediately to Indero, the latest change in an effort to become dually focused on both rheumatology and dermatology.
As Innovaderm, Indero has 25 years of experience in clinical dermatology research, the company said in a March 7 release. The firm chose to expand into rheumatology because many inflammatory and autoimmune conditions that affect the skin also impact the musculoskeletal system, according to the release.
“Our dual-focus, interdisciplinary approach allows us to support clinical studies for a wide range of rheumatology and dermatology conditions,” Indero CEO Jeff Smith said in the release. “The immune-mediated nature of both disease areas means that we are perfectly positioned to support clinical research across these specialties.”
Smith took over the chief executive role from founder Robert Bissonnette, M.D., last month as part of Indero’s plan to specialize in both dermatology and rheumatology. Smith started his career at German pharma Bayer and then spent 12 years at gastrointestinal-focused CRO Alimentiv, including six and a half years as its CEO.
Smith’s appointment followed the hiring of Ina Zschocke, Ph.D., as executive vice president of European operations and strategy in November 2024. Zschocke previously founded a dermatology CRO of her own called SCIderm.
Indero operates in North America, Europe, Latin America and the Asia-Pacific region, according to its website.